Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765101 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HTTPGRADRA2AADRA2B | |
| SCHEMBL1974542 | 0.71 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL7220752 | 0.71 | MEN1 (0.45) | MEN1KMT2AALDH1A1MAPTHTT | |
| Hydrochloric Acid SCHEMBL27558537 | 0.68 | PGR (0.56) | MEN1KMT2AALDH1A1HTTHSD17B10 | |
| SCHEMBL3970818 | 0.67 | PGR (0.39) | MEN1KMT2AALDH1A1HTTPGR | |
| SCHEMBL10533117 | 0.67 | ALDH1A1 (0.48) | ALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL27774844 | 0.66 | ALOX5 (0.53) | MEN1KMT2AALDH1A1PKMHSD17B10 | |
| SCHEMBL22097498 | 0.66 | MYC (0.43) | — | |
| SCHEMBL17238837 | 0.66 | MAOA (0.34) | ALDH1A1PKMHTTALOX5 | |
| SCHEMBL9153713 | 0.66 | HTR4 (0.41) | ALDH1A1PKMADRA2AHTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6447748-B1 | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010006619-A1 | Compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2001-07-05 | — | — | US | disclosed |
| US-6015543-A | DIAGNOSIS OF TUMORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5993777-A | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5911970-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0821594-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032968-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0650372-A4 | COMPOUNDS FOR CANCER IMAGING AND THERAPY. | JOHN CHRISTY S (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0650372-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994026314-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006619-A1 | Compounds for cancer imaging and therapy | SIGMAR1, TMEM97, ADRB3 | MEN1 245/4885KMT2A 3963/4885ALDH1A1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.